Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
A small molecule rather than a peptide: the first-in-class direct allosteric activator of AMPK (Poxel SA). It was studied in NASH/MASH and later moved into rare-disease programmes, ADPKD and X-linked adrenoleukodystrophy.
Size: 10 mg
No published analyses yet.
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Lower regimen | 250 mg once daily, oral | Starting dose |
| Split regimen | 250 mg twice daily (500 mg/day) | Increase if needed |
| Main studied regimen | 500 mg once daily | Maximum in this schedule |
Share your experience
No reviews yet. Tell others what you think of this product.
PXL770 is studied in metabolic research for its direct activation of AMPK, the enzyme pathway linked to fatty-acid oxidation and glucose regulation. It is not a peptide but a low-molecular-weight synthetic compound (a small molecule) for oral use, developed by the French company Poxel SA, which positioned it as the first-in-class direct activator of AMPK — a substance that binds the AMPK enzyme complex itself and activates it allosterically, unlike metformin or AICAR, which raise AMPK activity indirectly, by changing the cell's energy status.
AMPK (AMP-activated protein kinase) works as the cell's "fuel sensor": when the ATP/AMP ratio falls, it suppresses anabolic pathways, in particular de novo lipogenesis, and switches on fatty-acid oxidation. That is why direct AMPK activation has been considered a target in metabolic research for decades.
What the studies showed. In a phase 1b study in people with insulin resistance and NAFLD, PXL770 lowered de novo lipogenesis, so the target mechanism was confirmed in humans. However, the pivotal randomised, double-blind, placebo-controlled phase 2a study STAMP-NAFLD (120 participants, 12 weeks) did not meet its primary endpoint: the reduction in liver fat content versus placebo was not statistically significant (p=0.076 and p=0.084 for the two active regimens). This must be stated plainly: the compound did not "prove efficacy", it showed a signal that did not cross the significance threshold.
After that, Poxel effectively wound down the large NASH programme and refocused PXL770 on rare diseases, where the preclinical data looked stronger: autosomal dominant polycystic kidney disease (ADPKD) and X-linked adrenoleukodystrophy / adrenomyeloneuropathy. The FDA granted the compound orphan-drug status for ADPKD and Fast Track for X-ALD. These data remain mainly preclinical to date (cell and mouse models).
Status. The listing is "expected". A detailed analysis of the mechanism, the evidence base and the limitations is in the PXL770 monograph; other metabolic compounds are in the Metabolic compounds section.
